Zacks Investment Research lowered shares of Caladrius Biosciences (NASDAQ:CLBS) from a hold rating to a sell rating in a research note issued to investors on Wednesday.
According to Zacks, “Caladrius Biosciences, Inc. is an immunotherapy company which specializes in cell process optimization, development and manufacturing. Its product candidate consists of NBS20, a targeted cancer immunotherapy product for the treatment of metastatic melanoma; NBS10, an ischemic repair product to preserve heart muscle function following an acute myocardial infarction and NBS03D, an immune modulation product for the treatment of diabetes which are in different clinical trials. Caladrius Biosciences, Inc., formerly known as NeoStem, Inc., is headquartered in New York. “
Separately, HC Wainwright reiterated a buy rating and set a $7.00 price target on shares of Caladrius Biosciences in a research report on Friday, November 10th.
Shares of Caladrius Biosciences (NASDAQ CLBS) opened at $4.08 on Wednesday. Caladrius Biosciences has a 52 week low of $2.63 and a 52 week high of $7.79. The company has a market cap of $38.64, a price-to-earnings ratio of -1.97 and a beta of 1.59.
Caladrius Biosciences (NASDAQ:CLBS) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.41. equities research analysts forecast that Caladrius Biosciences will post -2.54 earnings per share for the current year.
A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc. increased its stake in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) by 2.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 155,380 shares of the biotechnology company’s stock after buying an additional 4,163 shares during the period. Vanguard Group Inc.’s holdings in Caladrius Biosciences were worth $723,000 at the end of the most recent quarter. 6.41% of the stock is currently owned by hedge funds and other institutional investors.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.